A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study Journal Article
| Authors: | Ross, R. W.; Galsky, M. D.; Scher, H. I.; Magidson, J.; Magidson, K.; Lee, G. S. M.; Katz, L.; Subudhi, S. K.; Anand, A.; Fleisher, M.; Kantoff, P. W.; Oh, W. K. |
| Article Title: | A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study |
| Abstract: | Background: Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer. Methods: Peripheral blood was prospectively collected from 62 men with castration-resistant prostate cancer on various treatment regimens who were enrolled in a training set at the Dana-Farber Cancer Institute (Boston, MA, USA) from August, 2006, to June, 2008, and from 140 patients with castration-resistant prostate cancer in a validation set from Memorial Sloan-Kettering Cancer Center (New York, NY, USA) from August, 2006, to February, 2009. A panel of 168 inflammation-related and prostate cancer-related genes was assessed with optimised quantitative PCR to assess biomarkers predictive of survival. Findings: A six-gene model (consisting of ABL2, SEMA4D, ITGAL, and C1QA, TIMP1, CDKN1A) separated patients with castration-resistant prostate cancer into two risk groups: a low-risk group with a median survival of more than 34·9 months (median survival was not reached) and a high-risk group with a median survival of 7·8 months (95% CI 1·8-13·9; p<0·0001). The prognostic utility of the six-gene model was validated in an independent cohort. This model was associated with a significantly higher area under the curve compared with a clinicopathological model (0·90 [95% CI 0·78-0·96] vs 0·65 [0·52-0·78]; p=0·0067). Interpretation: Transcriptional profiling of whole blood yields crucial prognostic information about men with castration-resistant prostate cancer. The six-gene model suggests possible dysregulation of the immune system, a finding that warrants further study. Funding: Source MDX. © 2012 Elsevier Ltd. |
| Journal Title: | Lancet Oncology |
| Volume: | 13 |
| Issue: | 11 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2012-11-01 |
| Start Page: | 1105 |
| End Page: | 1113 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(12)70263-2 |
| PROVIDER: | scopus |
| PUBMED: | 23059047 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 December 2012" - "CODEN: LOANB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work